The confusing start-up tax break.
Australia's new start-up CGT concession has a key eligibility test that hasn't been written yet — and that's just the beginning of the navigation problem.
The government's new Innovative Business CGT Concession sounds, on paper, like exactly the kind of thing Australia's start-up ecosystem needs: a capital gains tax break for early investors in innovative companies, designed to unlock more risk capital and reward the people who back new ideas early. The problem is not the intention. The problem is that reading the actual eligibility conditions feels like being handed a maze and told to find the door yourself.
The eligibility test that hasn't been written yet
Start with the eligibility conditions as they actually appear. To access the concession, a company must have been operating for no more than 15 years. Its aggregated annual turnover must be below $50 million. The investor must have held the equity for at least three years before selling. And the company must satisfy something called the "innovation requirements," which are detailed enough that the government is releasing a separate draft legislative instrument just to help companies self-assess whether they qualify. That instrument is not yet public. It is part of the consultation process. So the test that determines eligibility for the entire scheme is, at this point, still being written.
This is not unusual for exposure draft legislation. Consultation exists precisely because the details need work. But it is worth being clear about what it means in practice: a founder or early investor trying to understand today whether a given company will qualify for the IBCC in the future cannot fully answer that question yet. The rules are still being designed.
The incentive functions, in practice, as a reward for tax advisory capacity as much as for innovation.
The time windows interact in ways that aren't obvious
Even setting the self-assessment instrument aside, the interaction of the eligibility conditions is not simple. A company has 15 years to qualify as an innovative start-up. Its turnover must stay below $50 million during that window. The investor must hold equity for three years before a CGT event. These time periods can interact in non-obvious ways depending on when equity is issued, when the company grows past the threshold, and when a sale occurs. That kind of interaction is exactly the type of question that generates professional fees.
The R&D Tax Incentive changes sitting alongside the IBCC in the same draft legislation add another layer. The R&DTI reforms include a reduction in the intensity threshold on the non-refundable offset, from 2 per cent to 1.5 per cent, an increase to the maximum expenditure threshold to $200 million, a general 10-year operating limit on refundable offset access, and a separate 15-year window for biotech and medtech firms recognising their longer regulatory timelines. These are all reasonable design choices. They may even be good design choices. But stacked together with the IBCC conditions, they form a policy environment where the question "does this apply to my business" requires mapping multiple thresholds, time limits, and sector classifications before you can answer.
The concession rewards tax advisory capacity more than innovation
This is a recurring structural problem with Australian tax policy. As The Bearing has covered before, the compliance burden required to access tax concessions tends to fall hardest on the businesses least equipped to bear it. A well-resourced company with an in-house finance team or an established relationship with a Big Four firm will have its advisers across the IBCC rules within weeks of the final legislation passing. A two-person biotech operating out of a co-working space in Brisbane will be reading guidance documents late at night and hoping they have understood them correctly.
The perverse result is that the incentive functions, in practice, as a reward for tax advisory capacity as much as for innovation. The broader incentive design question is whether governments can reliably target this kind of redistribution toward its intended beneficiaries once the eligibility conditions grow complex enough to require professional interpretation.
The government is clearly trying to get this right. The consultation process is real, the revenue estimates are modest at $160 million for the IBCC and $60 million for the R&DTI reforms over the forward estimates, and the design reflects genuine engagement with how start-ups and venture capital actually work. But good intentions expressed through complex legislation do not automatically reach the people they are aimed at.
The start-up that most needs patient early capital is rarely the start-up with the clearest view of its own tax position. That gap, between the policy's targets and the policy's likely beneficiaries, is baked into the design. It will not be resolved by more consultation. It will only be resolved by simpler rules.
Sources
Treasury Ministers — Exposure draft legislation: tax reforms to support innovation and investment
The Bearing — Tax Reform's Hidden Cost: What Small Business Actually Pays When Government Simplifies
The Bearing — Budget's Innovation Bet: Who Bears the Cost When Incentives Misfire?
Frequently Asked Questions
What is the Innovative Business CGT Concession and who does it apply to?
The Innovative Business CGT Concession is a capital gains tax discount for early investors in eligible Australian start-ups. To qualify, the company must be less than 15 years old, have aggregated annual turnover below $50 million, and meet a self-assessed innovation test, while the investor must have held the equity for at least three years.
Why is the IBCC innovation test hard to satisfy?
The innovation test requires companies to self-assess their eligibility, but the legislative instrument setting out exactly how to do that has not yet been finalised — it is still part of the government's consultation process. A founder or investor cannot fully determine today whether their company will qualify under the final rules.
Does the IBCC actually help early-stage start-ups or mainly larger, better-resourced firms?
In practice, the concession is most accessible to companies with professional tax advisers who can map the interaction of multiple eligibility thresholds and time limits. The start-ups that most need early capital are typically the least equipped to navigate that complexity, which means the concession is likely to disproportionately benefit better-resourced firms.
How much does the IBCC cost the federal budget?
The government estimates the IBCC will cost approximately $160 million over the forward estimates, with a further $60 million for the accompanying R&D Tax Incentive reforms. These are relatively modest figures, though the article does not compare them directly to the compliance costs the scheme imposes on firms trying to access it.
What changes are being made to the R&D Tax Incentive at the same time?
The same draft legislation introduces a new 1.5 per cent intensity threshold on the non-refundable R&DTI offset, raises the maximum expenditure threshold to $200 million, and creates differentiated operating windows — 10 years generally and 15 years for biotech and medtech firms. These changes apply to a far broader set of companies than the IBCC.